AstraZeneca PLC 

AstraZeneca PLC (LSE: AZN) is an FTSE 100 listed science-led biopharmaceutical company, which focuses on the development, commercialization, and discovery of prescription medicines. 

FY23 Results (Released on 08 February 2024)

• Revenue Update: The company reported the total revenue improved by 6% to USD 45,811 mn during FY23, despite of a decline of USD 3,736 mn in sales from COVID-19 medicines. Excluding COVID-19 medicines, the total sales improved by 15% whereas the product sales grew by 14$ in FY23.
• Improved Financial Performance: The company reported that the Gross Profit improved by 17% to USD 37,543 mn in FY23 as compared to USD 31,960 mn in pcp, whereas the Operating Porift more than doubled to USD 8,193 mn in FY23 versus pcp. The Profit after tax increased by 81% to USD 5,961 mn in the reported period(FY23) as compared to USD 3,293 mn in pcp.
• Dividend: The management announced the second interim dividend of USD 1.97 per share which will be paid on 25 March 2024. This makes the total dividend of USD 2.90 per share for FY23.
• Outlook: The management expects the total revenue to increase by a low double digit to low teens in percentage, whereas the Core EPS is estimated to improve by a low digit to low teens percentage for FY24 at CER basis.

Share Price Chart

Markets are trading in a highly volatile zone currently due to certain macroeconomic issues and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.

AstraZeneca PLC (LSE: AZN) was trading at the closing market price of GBX 9,761.00  (as of 09 February 2024)

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is 09 February 2024. The reference data in this report has been partly sourced from REFINITIV.

Note 3: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.

Note 4: Dividend Yield may vary as per the stock price movement.